Luncheon with the Experts: Jason S. Starr, DO
Peptide Receptor Radionuclide Therapy
One of the most significant treatment options for neuroendocrine cancer patients became available with the 2018 FDA approval of Lutathera®, the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT).
NET experts Dr. Emily Bergsland, Dr. Pamela Kunz, Dr. Erik Mittra and Dr.
Jonathan Strosberg describe the treatment, how it works, and the benefits for patients.
What do physicians look forward to in the future for PRRT?
What Is Carcinoid Heart Disease? With Jerome Zacks, MD
Carcinoid heart disease (CHD) occurs in patients with advanced neuroendocrine tumors (NETs) and carcinoid syndrome, usually involving the right-sided heart valves. Cardiologist and neuroendocrine cancer expert Jerome S. Zacks, MD describes carcinoid heart disease, its signs and symptoms, and treatments.
Nutrition for Neuroendocrine Tumor Patients with Leigh Anne Burns, RDN
Neuroendocrine Tumor (NET) nutrition expert Leigh Anne Burns, RDN, answers questions about NETs and Nutrition. Questions include, how can a NET patient increase protein intake throughout the day?
Luncheon with the Experts: James Howe, MD
Luncheon with the Experts: Jonathan Strosberg, MD
Meet Dr. Strosberg. As a medical oncologist, he leads the Neuroendocrine Tumor Division and the Gastrointestinal Department Research Program at the Moffitt Cancer Center in Tampa, Florida. He has published over one hundred articles on the diagnosis and management of neuroendocrine malignancies in many prestigious medical journals including the New England Journal of Medicine, Lancet, and The Journal of Clinical Oncology.
Luncheon with the Experts: Robert Ramirez, DO, FACP
Meet Dr. Ramirez. He splits his clinical and research duties between the Ochsner Lung Cancer Multidisciplinary Program and the Ochsner Kenner/LSU Multidisciplinary Neuroendocrine Clinic in Louisiana. He has clinical and research interests in neuroendocrine tumors of the lung including DIPNECH, typical and atypical carcinoids, as well as lung cancer, specifically non-small cell and small cell cancers.
COVID-19: Your Health and Safety with Lowell Anthony, MD
Neuroendocrine tumor (NET) expert, Lowell Anthony, MD, answers questions neuroendocrine cancer patients have about the COVID-19 pandemic. Questions include: Does immunotherapy offer any protection against COVID19?
Clinical Trials: Neuroendocrine Tumors
“Clinical trials are critical for neuroendocrine tumor patients,” says Lowell Anthony, MD. “Until this disease is cured we have to be constantly looking at alternative management.”
NET experts Dr. Lowell Anthony, Dr. Aman Chauhan, Dr. Shikha Jain, Dr. Pamela Kunz, Dr. Erik Mittra, and Dr. Robert Ramirez discuss the phases of clinical trials, trials that have brought new treatment options for NET patients in recent years, and how patients can benefit from participating in trials.
Neuroendocrine tumor clinical trials are listed at https://clinicaltrials.gov/.
COVID-19: Your Health and Safety with Aman Chauhan, MD
Neuroendocrine tumor (NET) expert, Aman Chauhan, MD, answers questions neuroendocrine cancer patients have about the COVID-19 pandemic. Questions include: Is it okay to delay NET treatments, like somatostatin analogues, PRRT, or surgery, at this time?
Dr. Chauhan, medical oncologist, is an Assistant Professor of Medicine and Director of NET Theranostics at the UK Markey Cancer Center in Lexington, Kentucky. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small carcinomas.
ABCs of Neuroendocrine Cancer: 2020 Update
In the dynamic world of diagnosing and treating people living with neuroendocrine tumors (NETs), four expert physicians discuss everything from the increased incidence of NETs to symptoms of the disease and how to live with NETs for many years. What is unique about NETs? Where do NETs form in the body? What are the most recent advances in imaging and treatment options? Dr. Emily Bergsland, Dr. Pamela Kunz, Dr. Rodney Pommier, and Dr. Edward Wolin provide an overview about this uncommon cancer and offer patients perspectives from key opinion leaders in the field.
Lung Neuroendocrine Tumors and DIPNECH
Up to a quarter of all neuroendocrine tumors (NETs) originate in the lung. Neuroendocrine cancer expert Robert Ramirez, DO, FACP, describes the four types of lung neuroendocrine tumors, common respiratory symptoms, misdiagnoses, treatment options, and DIPNECH (diffuse idiopathic pulmonary neuroendocrine cell hyperplasia). Dr. Ramirez’s patient, Paige, experienced debilitating fatigue for months before being diagnosed with a lung NET. She emphasizes the importance of seeing NET specialists for this uncommon cancer. And hear from oncology nurse navigator Pamela Ryan, who has worked with the NET community for 15 years, about the advances she’s seen in NET imaging and treatments, and her hopes for the future.
Surgery for Neuroendocrine Tumors
Many doctors have historically considered surgery the first and best option for treating a neuroendocrine tumor (NET), when appropriate for their patients. But with all the treatments that have emerged over the past 10 years, as well as new perspectives on treating these tumors, is that still the case? NET experts Dr. Alexandra Gangi, Dr. Rodney Pommier, and Dr. Mark Lewis weigh in on surgery's role in the treatment process, including: which patients are ideal surgical candidates, when is surgery not an option, at what point in sequencing of treatments does surgery fall, and what new developments have occurred that make the chances of removing a NET through surgery more likely. Dr. Lewis provides a unique perspective on surgery as an oncologist and NET patient who had the Whipple surgical procedure himself! Find out more about NETs at https://www.carcinoid.org/